Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Current Liabilities: 2024-2025

Historic Total Current Liabilities for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $121.3 million.

  • Kura Oncology's Total Current Liabilities rose 200.47% to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 200.47%. This contributed to the annual value of $78.7 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Kura Oncology reported Total Current Liabilities of $121.3 million as of Q3 2025, which was up 13.18% from $107.2 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Total Current Liabilities peaked at $121.3 million during Q3 2025, and registered a low of $32.3 million during Q1 2024.
  • Moreover, its 2-year median value for Total Current Liabilities was $78.7 million (2024), whereas its average is $71.9 million.
  • Data for Kura Oncology's Total Current Liabilities shows a peak YoY surged of 220.39% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Total Current Liabilities (Quarterly) stood at $78.7 million in 2024, then spiked by 200.47% to $121.3 million in 2025.
  • Its Total Current Liabilities stands at $121.3 million for Q3 2025, versus $107.2 million for Q2 2025 and $89.8 million for Q1 2025.